Betulinic Acid Improves Cardiac-Renal Dysfunction Caused by Hypertrophy through Calcineurin-NFATc3 Signaling

Mi-Hyeon Hong1,2, Se-Won Na1,2, Youn-Jae Jang1,2

  • 1Hanbang Cardio-Renal Research Center, Wonkwang University, Iksan 54538, Korea.

Nutrients
|October 23, 2021
PubMed

Insights

Betulinic acid (BA) effectively treats cardiac hypertrophy and renal dysfunction in rats. This natural compound improved heart function and reduced cardiac biomarkers, offering potential as a functional material.

Area of Science:

  • Cardiovascular Pharmacology
  • Natural Product Chemistry
  • Renal Physiology

Background:

  • Cardiac hypertrophy is a major cause of heart failure, mortality, and morbidity worldwide.
  • Existing treatments for cardiac hypertrophy and associated renal dysfunction are limited.
  • Betulinic acid (BA), a natural compound, exhibits various physiological effects, but its role in cardiac hypertrophy is unexplored.

Purpose of the Study:

  • To investigate the effects of Betulinic acid (BA) on isoprenaline (ISO)-induced cardiac hypertrophy in Sprague Dawley rats.
  • To evaluate BA's impact on cardiac function, cardiac hypertrophy biomarkers, and related signaling pathways.
  • To assess BA's efficacy in mitigating renal dysfunction secondary to cardiac hypertrophy.

Main Methods:

  • Cardiac hypertrophy was induced in Sprague Dawley rats using daily intraperitoneal injections of isoprenaline (ISO) for 28 days.
  • Betulinic acid (BA) (10 or 30 mg/kg/day) or propranolol (positive control) was administered orally from day 14.
  • Cardiac and left ventricular weights, echocardiography, cardiac hypertrophy biomarkers (β-MHC, ANP, BNP, LDH, CK-MB), renal function indicators (creatinine clearance, BUN), and calcineurin/NFATc3 signaling were analyzed.

Main Results:

  • BA treatment significantly reduced cardiac and left ventricular weights in ISO-induced hypertrophied hearts.
  • Echocardiography confirmed BA's improvement of cardiac function impaired by ISO.
  • BA significantly decreased elevated cardiac hypertrophy biomarkers and restored renal function indicators (creatinine clearance, BUN) aggravated by ISO, by inhibiting calcineurin/NFATc3 signaling.

Conclusions:

  • Betulinic acid demonstrates significant efficacy in ameliorating cardiac hypertrophy and associated renal dysfunction.
  • BA improves cardiac function and reduces hypertrophy markers by modulating the calcineurin/NFATc3 signaling pathway.
  • These findings suggest BA holds potential as a functional material for managing cardiac and renal dysfunction.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
569
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
94
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
481
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
529
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
1.1K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
101